D60-D64

Document the specific type of aplastic anemia, its etiology (if known), and severity. Clearly distinguish between acquired and constitutional forms, and specify if it's severe, non-severe, or moderate. This detail is crucial for accurate coding and risk adjustment.

Example: S: 45 y/o F presenting with progressive fatigue, recurrent epistaxis, and frequent infections over 3 months. Pt denies recent travel, new medications, or toxic exposures. O: PE notable for pallor, petechiae on lower extremities, and oral thrush. Labs show pancytopenia (WBC 1.5, Hgb 7.2, Plt 28k). Bone marrow biopsy confirms hypocellular marrow, consistent with severe aplastic anemia. Etiology presumed idiopathic after extensive workup ruling out drug/toxin exposure, viral infections, and inherited syndromes. A: Acquired severe aplastic anemia (D61.2), manifesting with thrombocytopenic purpura (D69.3), neutropenic fever (R50.81), and oral candidiasis (B37.0). P: Initiate immunosuppressive therapy (ATG, cyclosporine). Refer to transplant center for evaluation. Continue packed red blood cell and platelet transfusions as needed. Closely monitor for infections. Patient's severe pancytopenia and associated complications represent a high burden of illness. Billing Focus: Explicit mention of 'acquired,' 'severe,' and 'idiopathic' provides maximum specificity. Listing associated conditions (thrombocytopenic purpura, neutropenic fever, candidiasis) supports higher E&M levels and medical necessity. Risk Adjustment: 'Acquired severe aplastic anemia' (D61.2) is an HCC-qualifying diagnosis (HCC 48/66). Documenting severity ('severe') and active management of complications (transfusions, immunosuppression, infection treatment) reinforces the chronic, debilitating nature of the condition and validates the high risk adjustment score. The comprehensive list of current problems demonstrates ongoing management of the condition's impact.

Billing Focus: Specificity of diagnosis (acquired, severe, idiopathic), documentation of all associated complications (thrombocytopenic purpura, neutropenic fever, candidiasis), and active management of these conditions.

Clearly document the clinical manifestations, laboratory findings, and diagnostic procedures that support the diagnosis. Include the results of a bone marrow biopsy/aspirate as this is definitive for aplastic anemia.

Example: S: Patient reports extreme fatigue, dyspnea on exertion, and recent gingival bleeding. O: Initial CBC revealed Hgb 8.0 g/dL, WBC 2.8 K/uL, and Platelets 50 K/uL. Repeat labs confirm persistent pancytopenia. Bone marrow aspirate and biopsy performed on [Date] showed profoundly hypocellular marrow for age (<25% cellularity) with normal myeloid and megakaryocytic maturation but markedly reduced hematopoietic precursors, consistent with aplastic anemia. Cytogenetics normal. No evidence of dysplasia or abnormal blasts. A: Moderate aplastic anemia, likely acquired idiopathic (D61.9). This patient's condition is stable with close monitoring, but still requires ongoing management. Billing Focus: Explicitly stating 'hypocellular marrow,' 'normal myeloid/megakaryocytic maturation,' and 'reduced hematopoietic precursors' directly from the pathology report substantiates the diagnosis. Documenting persistent pancytopenia and the date of the definitive diagnostic procedure (bone marrow biopsy) supports medical necessity for ongoing care. Risk Adjustment: While D61.9 ('Aplastic anemia, unspecified') is less specific than D61.2, clear documentation of the underlying pancytopenia and a history of definitive diagnosis still validates a chronic, significant condition. Documentation of 'moderate' severity, though not specifically coded, provides clinical context for risk adjustment models that consider overall patient health status. Ongoing monitoring and symptom management contribute to resource utilization metrics.

Billing Focus: Inclusion of key diagnostic findings (bone marrow biopsy results, persistent pancytopenia) and ruling out other etiologies (cytogenetics, no dysplasia/blasts).

If the aplastic anemia is secondary to another condition (e.g., drug-induced, viral, post-radiation), ensure the causal relationship is clearly stated in the documentation. This linkage is critical for accurate coding and understanding disease progression.

Example: S: Patient presents for follow-up regarding aplastic anemia. Patient was prescribed [Drug Name, e.g., Chloramphenicol] for a severe infection 6 months ago. Developed severe pancytopenia 2 months later. O: Labs continue to show pancytopenia (WBC 1.2, Hgb 6.8, Plt 25k). Current medications include only supportive care. A: Severe aplastic anemia, drug-induced (D61.1), secondary to prior [Drug Name] use. Patient has been off the causative agent for 4 months but marrow has not recovered. This is a chronic, severe condition requiring ongoing management and potential stem cell transplant evaluation. P: Continue current transfusion protocol. Discuss options for immunosuppressive therapy. Close monitoring of CBC and infectious complications. Billing Focus: Directly linking 'drug-induced' aplastic anemia to the specific medication provides critical specificity for D61.1. Documentation of ongoing severe pancytopenia and lack of recovery despite cessation of the causative agent underscores the chronic nature and high complexity of management. Risk Adjustment: D61.1 (Drug-induced aplastic anemia) is an HCC-qualifying diagnosis. Explicitly stating the drug causality and documenting the persistent, severe nature of the anemia after drug cessation solidifies the HCC assignment and supports a high-risk score, reflecting the chronic and complex care required.

Billing Focus: Explicitly documenting the causative drug and the temporal relationship to the development of aplastic anemia. Stating the persistence of the condition.